For over a decade, the standard of care for high-risk MDS has remained a class of drugs called hypomethylating agents (HMAs).
Authors acknowledge that both the 2022 World Health Organization and International Consensus Classification myelodysplastic syndrome criteria sets have value, while sorting out their similarities and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results